Phio Pharmaceuticals Corp. (PHIO)
PHIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/0001683168-21-001062-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PHIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001533040 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$8.8M |
| Operating income | -$8.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $14.3M |
| Total assets | $15.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $10.6M cash; operating cash flow -$3.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 11,951,632 (2026-11-03); 10,764,428 a year earlier; 2,443,447 three years earlier. 3y figure adjusted for splits (1-for-9 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-9 on 2024-07-05 | Source 2024-07-05 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $91K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.2M | -$2.3M | $10.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$4.1M | -$4.0M | $13.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$4.0M | -$4.0M | $17.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$2.4M | -$2.1M | $21.0M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$2.4M | -$2.1M | $10.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$2.2M | -$2.5M | $10.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$1.8M | -$1.3M | $13.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$1.6M | -$1.4M | $5.4M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-04-08 |
| Latest annual report FORM 10-K | 10-K | 2026-03-05 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | DEFA14A | 2026-08-14 |
Source: SEC EDGAR submissions feed, 899 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.7% |
| 1 month | -17.5% |
| 3 months | -29.3% |
| Year to date | -26.6% |
| 1 year | -46.1% |
| From 52-week high | -53.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BFRG | Bullfrog AI Holdings Inc. | $0.4878 | -9.92% | $9.0M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| VTGN | Vistagen Therapeutics Inc. | $0.1843 | +2.11% | $8.5M |
| CALC | CalciMedica Inc. | $1.19 | -1.65% | $8.2M |
| MTVA | MetaVia Inc. | $1.21 | -7.31% | $8.1M |
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| RKTO | Rocket One Inc. | $0.3210 | +0.03% | $8.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier